KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Operating Income (2016 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Operating Income for 10 consecutive years, with $300.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Income rose 1134.48% year-over-year to $300.0 million, compared with a TTM value of $4.6 billion through Dec 2025, up 1618.81%, and an annual FY2025 reading of $2.2 billion, up 811.88% over the prior year.
  • Operating Income was $300.0 million for Q4 2025 at Teva Pharmaceutical Industries, down from $2.0 billion in the prior quarter.
  • Across five years, Operating Income topped out at $2.0 billion in Q3 2025 and bottomed at -$967.0 million in Q2 2022.
  • Average Operating Income over 5 years is $212.6 million, with a median of $189.0 million recorded in 2021.
  • The sharpest move saw Operating Income plummeted 1576.92% in 2024, then surged 36020.0% in 2025.
  • Year by year, Operating Income stood at $78.0 million in 2021, then plummeted by 1300.0% to -$936.0 million in 2022, then skyrocketed by 180.77% to $756.0 million in 2023, then tumbled by 103.84% to -$29.0 million in 2024, then soared by 1134.48% to $300.0 million in 2025.
  • Business Quant data shows Operating Income for TEVA at $300.0 million in Q4 2025, $2.0 billion in Q3 2025, and $1.8 billion in Q2 2025.